

Supplementary Table 1. Patients achieving sustained response and response in the overall population of patients with focal seizures

| | Placebo (n=418) | BRV 50 mg/day (n=161) | | BRV 100 mg/day (n=332) | | BRV 200 mg/day (n=249) | |
|--|--------------------|--------------------------|----------------------|---------------------------|----------------------|---------------------------|----------------------|
| | KM estimate (%) | KM estimate (%) | P-value ^a | KM estimate (%) | P-value ^a | KM estimate (%) | P-value ^a |
| ≥75% Sustained Response in Focal Seizure Reduction | | | | | | | |
| Sustained response from day 1 | 3.1 | 5.0 | .2842 | 10.8 | <.0001 | 9.3 | .0006 |
| Sustained response from day 84 | 6.7 | 13.0 | .0141 | 19.6 | <.0001 | 17.8 | <.0001 |
| KM estimates of patients achieving response ^b on day 1, % | 65.6 | 82.6 | <.0001 | 79.8 | <.0001 | 81.0 | <.0001 |
| ≥90% Sustained Response in Focal Seizure Reduction | | | | | | | |
| Sustained response from day 1 | 1.2 | 3.1 | .1144 | 6.9 | <.0001 | 5.3 | .0018 |
| Sustained response from day 84 | 2.4 | 4.3 | .2121 | 11.1 | <.0001 | 7.7 | .0012 |
| KM estimates of patients achieving response ^b on day 1, % | 65.1 | 82.6 | <.0001 | 78.9 | <.0001 | 81.0 | <.0001 |
| 100% Sustained Response in Focal Seizure Reduction | | | | | | | |
| Sustained response from day 1 | 0.5 | 2.5 | .0329 | 5.1 | <.0001 | 4.0 | .0008 |
| Sustained response from day 84 | 0.5 | 2.5 | .0329 | 5.4 | <.0001 | 4.0 | .0008 |
| KM estimates of patients achieving response ^b on day 1, % | 65.1 | 82.6 | <.0001 | 78.9 | <.0001 | 81.0 | <.0001 |

^aP values represent treatment differences in Kaplan Meier estimates vs placebo.

^bEstimates represent the response at any specific time point *not the sustained response* through the treatment period.

BRV, brivaracetam; KM, Kaplan-Meier

Supplementary Table 2. Patients achieving sustained response and response in the subpopulation of patients with FBTCS

| | Placebo (n=115) | BRV 50 mg/day (n=62) | | BRV 100 mg/day (n=100) | | BRV 200 mg/day (n=75) | |
|--|--------------------|-------------------------|----------------------|---------------------------|----------------------|--------------------------|----------------------|
| | KM estimate (%) | KM estimate (%) | P-value ^a | KM estimate (%) | P-value ^a | KM estimate (%) | P-value ^a |
| ≥75% Sustained Response in FBTCS Reduction | | | | | | | |
| Sustained response from day 1 | 15.7 | 25.8 | .1028 | 35.0 | .0011 | 41.3 | <.0001 |
| Sustained response from day 84 | 20.9 | 33.9 | .0588 | 45.0 | .0002 | 45.3 | .0004 |
| KM estimates of patients achieving response ^b on day 1, % | 87.8 | 95.2 | .1151 | 95.0 | .0652 | 92.0 | .3608 |
| ≥90% Sustained Response in FBTCS Reduction | | | | | | | |
| Sustained response from day 1 | 14.8 | 22.6 | .1941 | 34.0 | .001 | 37.3 | .0004 |
| Sustained response from day 84 | 15.7 | 24.2 | .1651 | 36.0 | .0006 | 40.0 | .0002 |
| KM estimates of patients achieving response ^b on day 1, % | 87.8 | 95.2 | .1151 | 95.0 | .0652 | 92.0 | .3608 |
| 100% Sustained Response in FBTCS Reduction | | | | | | | |
| Sustained response from day 1 | 14.8 | 22.6 | .1941 | 32.0 | .0027 | 36.0 | .0007 |
| Sustained response from day 84 | 14.8 | 22.6 | .1941 | 32.0 | .0027 | 36.0 | .0007 |
| KM estimates of patients achieving response ^b on day 1, % | 87.8 | 95.2 | .1151 | 95.0 | .0652 | 92.0 | .3608 |

^aP values represent treatment differences in Kaplan Meier estimates vs placebo.

^bEstimates represent the response at any specific time point *not the sustained response* through the treatment period.

BRV, brivaracetam; FBTCS, focal to bilateral tonic-clonic seizures; KM, Kaplan-Meier.